Related Experiment Video
Updated: May 3, 2026

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
Hypotension among patients with liver failure treated by artificial liver support system: risk factors and coping
Junjie Liu1, Xiufen Liu1, Muqingzi Wang1
1Department of Surgery, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing, Jiangsu, China.
Background:
Artificial Liver Support System (ALSS) is a core therapeutic modality for liver failure, but hypotension is a common and severe complication during treatment, which may lead to treatment interruption and poor prognosis. This study aims to explore the independent risk factors of hypotension complicating ALSS treatment for liver failure, construct a predictive model, and provide evidence for clinical coping strategies.
Methods:
A retrospective cohort study was conducted. According to the occurrence of hypotension during treatment, they were divided into the hypotension group and the non-hypotension group. Clinical data of the two groups were collected and analyzed.
Results:
216 patients with liver failure who received ALSS treatment were included. Multivariate logistic regression analysis confirmed that age ≥ 65 years (OR = 2.379, 95%CI:1.568 ~ 3.605), BMI < 19 kg/m² (OR = 2.782, 95%CI:1.825 ~ 4.226), ALSS treatment duration > 4 h (OR = 2.598, 95%CI:1.689 ~ 3.987), hypokalemia (OR = 2.193, 95%CI:1.452 ~ 3.298) and hypoalbuminemia (OR = 3.099, 95%CI:2.015 ~ 4.756) were independent risk factors for hypotension (all P < 0.001). The constructed scoring predictive model had excellent discriminative efficacy with an AUC of 0.888 (95%CI:0.840 ~ 0.936), and the highest Youden's index (0.642) was obtained when the scoring threshold was 6.5 points.
Conclusion:
The simplified scoring model exhibits favorable predictive efficacy, enabling early identification and risk stratification of high-risk patients. Implementation of multidimensional prevention strategies-including precision treatment optimization, individualized nursing interventions, and integrated process management-may reduce the incidence of hypotension and improve treatment safety.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Heart Failure VI: Adjunct Therapies
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Heart Failure V: Medical Management
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

